Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Tobacco Use Disorder 1Thyroid Neoplasms 1Stomach Neoplasms 1Mouth Neoplasms 1Lichen Planus 1Leukokeratosis, Hereditary Mucosal 1Fanconi Anemia 1Erythroplasia 1

Interventions

Oxaliplatin 66pembrolizumab 47Fluorouracil 44Capecitabine 39Nivolumab 33Leucovorin 32Paclitaxel 28Trastuzumab 20Docetaxel 19Cisplatin 18S 1 (combination) 17Bevacizumab 15Irinotecan 14Drug Therapy 14tislelizumab 12Ramucirumab 12Cyclophosphamide 12fludarabine 10Carboplatin 10sintilimab 9Radiotherapy 9Magnetic Resonance Spectroscopy 9trastuzumab deruxtecan 8atezolizumab 8Specimen Handling 8Biopsy 8durvalumab 7Surgical Procedures, Operative 7Gemcitabine 7zolbetuximab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × Molecular Diagnostic Techniques × 1 year × Clear all
NCT04600466 2026-04-14

Molecular and Epidemiological Risk Factors in the Development of Gastric Cancer

The University of Texas Health Science Center at San Antonio

Terminated
129 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡